Nventa granted U.S. patent covering heat shock protein fusion to treat influenza

    SAN DIEGO, CA, Jan. 30 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX:NVN) announced today that the U.S. Patent and Trademark Office has issued
Patent Number 7,157,089 to Nventa, further strengthening the Company's
intellectual property position and portfolio. The patent provides coverage for
compositions of fusion proteins comprised of an influenza antigen fused to a
heat shock protein (Hsp), as well as DNA encoding such fusion proteins and
their use in immunotherapy.
    In addition, the Company announced that the corresponding European Patent
(EP 941,315 B1) has passed the required European patent opposition period
    "Given the continued need for influenza treatments and growing concerns
about pandemic outbreak, we are very pleased to have been issued the U.S.
patent covering our influenza compound," said Gregory M. McKee, President and
Chief Executive Officer at Nventa. "While our focus today is on developing
HspE7 for the treatment of serious human papillomavirus-related diseases, this
patent strengthens our ability to develop a heat shock fusion protein
targeting influenza, likely with the cooperation of a corporate,
not-for-profit or government partner. We are encouraged to have generated
promising preclinical data against common and avian flu types using prototypes
of Hsp fusion proteins with influenza antigens at a time that we believe there
are few companies working on a treatment in this space."

    About Influenza:

    Every year, 10 to 20 percent of Americans get sick with the flu
(influenza). In the United States, approximately 25 percent of the population
has flu-associated illness annually, leading to an average of 20,000 to 40,000
deaths per year. The U.S. Centers for Disease Control and Prevention (CDC)
estimates that 35 to 50 million Americans come down with the flu during each
flu season, which typically lasts from November to March.

    About Nventa Corporation:

    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa, please visit
the website located at www.nventacorp.com.

    This press release contains statements which, to the extent that they are
not recitations of historical fact may constitute forward-looking information
under applicable Canadian securities legislation or forward-looking statements
within the meaning of the United States Private Securities Litigation Reform
Act of 1995. Such forward-looking statements or information may include
financial and other projections as well as statements regarding the Company's
future plans, objectives, performance, revenues, growth, profits, operating
expenses or the Company's underlying assumptions. The words "may", "would",
"could", "will", "likely", "expect", "anticipate", "intend", "estimate",
"plan", "forecast", "project" and "believe" or other similar words and phrases
are intended to identify forward-looking statements or information. Persons
reading this press release are cautioned that such statements or information
are only predications, and that the Company's actual future results or
performance may be materially different.
    Forward-looking statements or information in this press release include,
but are not limited to, statements or information concerning the coverage
provided by this patent and the cooperation of a partner. Such forward-looking
statements or information involve known and unknown risks, uncertainties and
other factors that may cause our actual results, events or developments, to be
materially different from any future results, events or developments expressed
or implied by such forward-looking statements or information. Such factors
include potential challenges to our patent and the level of partner interest.
    Assumptions underlying our expectations regarding forward-looking
statements or information contained in this press release include, among
others, that challenges to our patent, if any, will not be successful, and we
will be successful in acquiring a partner to assist us with the development of
a heat shock fusion protein targeting influenza.
    For a complete discussion of the assumptions, risks and uncertainties
related to our business, you are encouraged to review our filings with
Canadian securities regulatory authorities on SEDAR at http://www.sedar.com.
Historical filings relating to the Company prior to the completion of the
Company's March 23, 2006 corporate reorganization, including Old Stressgen's
2005 Annual Information Form dated March 16, 2006 may be reviewed on SEDAR at
http://www.sedar.com under the SEDAR profile GVIC Publications Ltd.
    All forward-looking statements and information made herein are based on
our current expectations as of the date hereof and we disclaim any intention
or obligation to revise or update such forward-looking statements and
information to reflect subsequent events or circumstances, except as required
by law.

    %SEDAR: 00023483E

For further information:

For further information: Donna Slade, Director, Investor Relations, 6055
Lusk Boulevard, San Diego, CA, USA, 92121, Dir: (858) 202-4945,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890